logo
Twitter
Discord
Email
logo
Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

NASDAQ•KYMR
CEO: Dr. Bruce L. Booth DPHIL, Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-08-21
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Contact Information
200 Arsenal Yards Boulevard, Suite 230, Watertown, MA, 02472, United States
857-285-5300
www.kymeratx.com
Market Cap
$4.41B
P/E (TTM)
-18.1
45.8
Dividend Yield
--
52W High
$63.96
52W Low
$19.45
52W Range
94%
2.0
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2024

Financial Dashboard

Q3 2025 Data

Revenue

$2.76M-26.12%
4-Quarter Trend

EPS

-$0.94+14.63%
4-Quarter Trend

FCF

-$27.29M-45.42%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Strong Cash Position Cash, equivalents, securities total $978.7M as of September 30, 2025. Runway extends into the second half of 2028.
R&D Investment Surge Nine-month R&D expenses reached $232.7M, increasing $64.3M, driven primarily by STAT6 program costs.
Gilead Collaboration Active New Gilead deal generated $40.0M upfront; $2.8M revenue recognized in the nine months ended September 30, 2025.
Sanofi IRAK4 Advancement Sanofi advanced next-generation IRAK4 degrader (KT-485) into clinical testing; $33.6M revenue recognized in nine months.

Risk Factors

Net Loss Widening Nine-month net loss increased to $(224.4)M from $(153.1)M, anticipating continued substantial operating losses.
Lease Asset Impairment Recorded $3.9M incremental impairment charge on 2019 Lease due to continued worsening of office and lab space market.
Early Stage Development Company remains clinical-stage; success hinges on advancing STAT6, IRF5, and IRAK4 programs through clinical hurdles.
Financing Dependency Risk Expect substantial expense increases necessitating additional funding via equity, debt, or strategic collaborations to continue operations.

Outlook

STAT6 Program Advancement STAT6 program molecule KT-621 advanced into Phase 2b clinical trial for moderate to severe Atopic Dermatitis.
IRAK4 Next-Gen Focus Advance next-generation IRAK4 degrader (KT-485/SAR447971) into clinical testing with Sanofi planned for 2026.
Future Capital Needs Future capital requirements depend heavily on clinical trial success, demanding additional financing beyond 2028 runway.
IP Protection Strategy Continue efforts to obtain and maintain broad patent protection for proprietary TPD technology and pipeline assets.

Peer Comparison

Revenue (TTM)

Zai Lab LimitedZLAB
$441.63M
+24.1%
Soleno Therapeutics, Inc.SLNO
$98.68M
+2763.5%
Kymera Therapeutics, Inc.KYMR
$43.73M
-50.1%

Gross Margin (Latest Quarter)

Soleno Therapeutics, Inc.SLNO
98.3%
+0.0 pp
uniQure N.V.QURE
89.2%
+33.9 pp
NewAmsterdam Pharma Company N.V.NAMS
81.6%
-18.4 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ACLX$4.75B-25.6-43.0%8.5%
NAMS$4.41B-21.0-29.1%0.0%
KYMR$4.41B-18.1-33.4%7.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-28.0%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $2.76M-26.1%
    |
    EPS: $-0.94+14.6%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $11.48M-55.3%
    |
    EPS: $-0.95+63.8%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 9, 2025|
    Revenue: $22.10M+114.8%
    |
    EPS: $-0.82+18.8%
    Beat

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $47.07M-40.1%
    |
    EPS: $-2.98-18.3%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 31, 2024|
    Revenue: $3.74M-20.9%
    |
    EPS: $-0.82-8.9%
    Meet

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 7, 2024|
    Revenue: $25.65M+55.3%
    |
    EPS: $-0.58-13.4%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $10.29M+8.7%
    |
    EPS: $-0.69+9.5%
    Meet

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 22, 2024|
    Revenue: $78.59M+67.8%
    |
    EPS: $-2.52+10.6%
    Miss